Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Other Accumulated Expenses (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed Other Accumulated Expenses for 3 consecutive years, with $484000.0 as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses fell 22.06% to $484000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $484000.0 through Dec 2025, down 22.06% year-over-year, with the annual reading at $484000.0 for FY2025, 22.06% down from the prior year.
  • Other Accumulated Expenses hit $484000.0 in Q4 2025 for Compass Therapeutics, up from $141000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $621000.0 in Q4 2024 to a low of $137000.0 in Q1 2023.
  • Historically, Other Accumulated Expenses has averaged $306916.7 across 3 years, with a median of $277500.0 in 2024.
  • Biggest YoY gain for Other Accumulated Expenses was 158.75% in 2024; the steepest drop was 57.29% in 2024.
  • Year by year, Other Accumulated Expenses stood at $240000.0 in 2023, then skyrocketed by 158.75% to $621000.0 in 2024, then dropped by 22.06% to $484000.0 in 2025.
  • Business Quant data shows Other Accumulated Expenses for CMPX at $484000.0 in Q4 2025, $141000.0 in Q3 2025, and $384000.0 in Q2 2025.